Rationally Repurposing Ruxolitinib (Jakafi(®)) as a Solid Tumor Therapeutic

We determined whether the approved myelofibrosis drug ruxolitinib (Jakafi(®)), an inhibitor of Janus kinases 1/2 (JAK1 and JAK2), could be repurposed as an anti-cancer agent for solid tumors. Ruxolitinib synergistically interacted with dual ERBB1/2/4 inhibitors to kill breast as well as lung, ovaria...

Descripción completa

Detalles Bibliográficos
Autores principales: Tavallai, Mehrad, Booth, Laurence, Roberts, Jane L., Poklepovic, Andrew, Dent, Paul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2016
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4904019/
https://www.ncbi.nlm.nih.gov/pubmed/27379204
http://dx.doi.org/10.3389/fonc.2016.00142

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4904019/
https://www.ncbi.nlm.nih.gov/pubmed/27379204
http://dx.doi.org/10.3389/fonc.2016.00142

Ejemplares similares